Case number 1:21-cv-01797
Novartis Pharmaceuticals Corporation v. Crystal Pharmaceutical (Suzhou) Co., Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 14, 2022 | 54 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,135,192. (Attachments: # 1 Order)(nms) (Entered: 11/14/2022) (Order) (1) |
| Nov 14, 2022 | 54 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,135,192. (Attachments: # 1 Order)(nms) (Entered: 11/14/2022) (Main Document) (1) |
| Nov 14, 2022 | 53 | ORDER: Plaintiff's motions to dismiss Plaintiff's complaints against Defendant and Defendant's counterclaims against Plaintiff's U.S. Patents Nos. 9,517,226, 9,937,143, and 11,135,192 (C.A. No. 21-1347, D.I. 23; C.A. No. 21 1797, D.I. 22) are GRANTED. The complaints and counterclaims are DISMISSED without prejudice. Signed by Judge Richard G. Andrews on 11/14/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01347-RGA, 1:21-cv-01797-RGA(nms) (Entered: 11/14/2022) (1) |
| Nov 14, 2022 | 52 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 11/14/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01347-RGA, 1:21-cv-01797-RGA(nms) (Entered: 11/14/2022) (9) |
| Nov 4, 2022 | 51 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Preliminary Claim Constructions and Supporting Evidence filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 11/04/2022) (2) |
| Oct 28, 2022 | 50 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Initial Invalidity Contentions with Respect to the HF-PEF Patents filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 10/28/2022) (2) |
| Oct 26, 2022 | 49 | REDACTED VERSION of 46 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/26/2022 (nms). (Entered: 10/26/2022) (2) |
| Oct 11, 2022 | 48 | STIPULATION TO EXTEND TIME deadline to file a public redacted version of Novartis's Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Response to Discovery Dispute to October 24, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 10/11/2022) (2) |
| Oct 6, 2022 | 47 | REDACTED VERSION of 45 Letter, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 10/6/2022 (nms). (Entered: 10/06/2022) (Certificate of Service) (1) |
| Oct 6, 2022 | 47 | REDACTED VERSION of 45 Letter, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 10/6/2022 (nms). (Entered: 10/06/2022) (Exhibit A) (4) |
| Oct 6, 2022 | 47 | REDACTED VERSION of 45 Letter, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 10/6/2022 (nms). (Entered: 10/06/2022) (Main Document) (2) |
| Oct 4, 2022 | 46 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to discovery dispute letter. (Silver, Daniel) Modified on 10/4/2022 (nms). (Entered: 10/04/2022) (0) |
| Sep 29, 2022 | 45 | [SEALED] Letter to Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding infringement contentions. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 9/29/2022 (nms). (Entered: 09/29/2022) (0) |
| Sep 29, 2022 | 44 | NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions Against Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/29/2022) (2) |
| Sep 12, 2022 | 43 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Joint Initial Invalidity Contentions for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 09/12/2022) (2) |
| Sep 7, 2022 | 42 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Sep 6, 2022 | 41 | NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.'s Initial Disclosure Statement Pursuant to Fed. R. Civ. P. 26(a) and Paragraph 3 of the Delaware Default Standard for Discovery, including Electronically Stored Information filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 09/06/2022) (2) |
| Aug 29, 2022 | 40 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 39 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 38 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (0) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 21, 2022 | 37 | ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) (Entered: 07/21/2022) (0) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jul 19, 2022 | 36 | Redacted Document (13) Docket Text: REDACTED VERSION of [30] Reply Brief, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/19/2022 (nms). |
| Jul 15, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The redactions proposed at: D.I. 35 in 21-cv-1347-RGA; D.I. 682 in 20-md-2930-RGA; and D.I. 34 in 21-cv-1797-RGA, are APPROVED. Ordered by Judge Richard G. Andrews on 7/15/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01347-RGA, 1:21-cv-01797-RGA(nms) |
| Jul 14, 2022 | 34 | Declaration (3) Docket Text: DECLARATION in Support of [33] Redacted Document, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 7/14/2022 (nms). |
| Jul 14, 2022 | 33 | Certificate of Service (1) |
| Jul 14, 2022 | 33 | Exhibit 1-13 (161) |
| Jul 14, 2022 | 33 | Main Document (3) Docket Text: REDACTED VERSION of [28] Declaration, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # (1) Exhibits 1-13, # (2) Certificate of Service)(Gattuso, Dominick) Modified on 7/14/2022 (nms). |
| Jul 14, 2022 | 32 | Certificate of Service (1) |
| Jul 14, 2022 | 32 | Main Document (24) Docket Text: REDACTED VERSION of [27] Answering Brief in Opposition, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # (1) Certificate of Service)(Gattuso, Dominick) Modified on 7/14/2022 (nms). |
| Jul 14, 2022 | 31 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 7/14/2022 (nms). |
| Jul 6, 2022 | 29 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME public versions of Crystal's Sealed Filings to July 14, 2022 - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| Jul 6, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 672 in 20-md-2930-RGA; D.I. 29 in 21-cv-1797-RGA; D.I. 30 in 21-cv-1347-RGA) STIPULATION and Order to Extend Time to filed public versions of Crystal's Sealed Filings to July 14, 2022. Signed by Judge Richard G. Andrews on 7/6/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01347-RGA, 1:21-cv-01797-RGA(nms) |
| Jun 28, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 663 in 20-md-2930-RGA; D.I. 26 in 21-cv-1797-RGA; D.I. 27 in 21-cv-1347-RGA) STIPULATION and Order to Extend Time for briefing. Signed by Judge Richard G. Andrews on 6/28/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01347-RGA, 1:21-cv-01797-RGA(nms) |
| Jun 27, 2022 | 26 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION and Order to Extend Time - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 6/28/2022 (nms). |
| Jun 21, 2022 | 25 | Redacted Document (15) Docket Text: REDACTED VERSION of [23] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/22/2022 (nms). |
| Jun 15, 2022 | 24 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 14, 2022 | 22 | Text of Proposed Order (2) |
| Jun 14, 2022 | 22 | Main Document (2) Docket Text: MOTION to Dismiss Based upon Civil Action Nos. 21-1347 and 21-1797 and Their Associated Counterclaims - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Text of Proposed Order)(Silver, Daniel) |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 21 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | 20 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 16 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | 15 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 14 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 1, 2022 | 13 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 17, 2022 | 11 | Exhibit A-B (7) |
| Mar 17, 2022 | 11 | Main Document (2) Docket Text: DECLARATION of Service of Crystal Pharmaceutical (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 4/8/2022 (nms). |
| Mar 16, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Mar 2, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney C. Kyle Musgrove for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) |
| Mar 1, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Elizabeth M. Crompton for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Mar 1, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [10] MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP filed by Crystal Pharmaceutical (Suzhou) Co., Ltd. Signed by Judge Leonard P. Stark on 3/1/22. (ntl) |
| Feb 28, 2022 | 10 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| Feb 25, 2022 | 9 | Answer to Counterclaim (7) Docket Text: ANSWER to [7] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 4, 2022 | 8 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Crystal Pharmatech Co., Ltd. for Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| Feb 4, 2022 | 7 | Answer to Complaint (17) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jan 11, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Shannon K. Clark,Nicholas N. Kallas,Jared L. Stringham,Christina Schwarz,Laura K. Fishwick for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01794-LPS, 1:21-cv-01760-LPS, 1:21-cv-01797-LPS(mal) |
| Jan 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [6] MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 1/11/22. (ntl) |
| Jan 10, 2022 | 6 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, S (8) |
| Jan 10, 2022 | 6 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas)(Silver, Daniel) |
| Dec 29, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Dec 22, 2021 | 1 | Complaint* (1) |
| Dec 22, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (smg) |
| Dec 22, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number 11,135,193. (smg) |
| Dec 22, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/10/2021. Date of Expiration of Patent: 08/22/2033.Thirty Month Stay Deadline: 7/7/2023. (smg) |
| Dec 22, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) |
| Dec 22, 2021 | 1 | Civil Cover Sheet (2) |
| Dec 22, 2021 | 1 | Exhibit A (19) |
| Dec 22, 2021 | 1 | Main Document (10) Docket Text: COMPLAINT filed against Crystal Pharmaceutical (Suzhou) Co., Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3769156.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(smg) |
| Dec 22, 2021 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (smg) |
